Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$476.27 USD

476.27
490,764

+2.99 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $476.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall

by Zacks Equity Research

Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.

NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research

NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.

Tandem Diabetes' (TNDM) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic and international pump sales and shipments boosted the Q4 top line.

Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

by Zacks Equity Research

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test

by Zacks Equity Research

BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.

Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DEF

Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up

by Zacks Equity Research

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Medtronic (MDT) Progresses in SNM With Updated InterStim Label

by Zacks Equity Research

Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.

Globus Medical (GMED) Q4 Earnings Beat, U.S. Business Strong

by Zacks Equity Research

Globus Medical's (GMED) spinal implant business performance varies by region in Q4.

Ecolab's (ECL) Certified Program to Build Customer Confidence

by Zacks Equity Research

Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.

Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.

Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.

NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater

by Zacks Equity Research

Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.

CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y

by Zacks Equity Research

The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.

TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows

by Zacks Equity Research

TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.

Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.

by Zacks Equity Research

Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry

by Zacks Equity Research

Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.

New Study Favors Myriad Genetics' (MYGN) GeneSight Test

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

by Zacks Equity Research

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2

by Zacks Equity Research

Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.